Discovery of Modulators of Protein-Protein Interactions: Current Approaches and Limitations

被引:1
作者
Meireles, Lidio M. C. [1 ]
Mustata, Gabriela [1 ]
机构
[1] Univ Pittsburgh, Dept Computat & Syst Biol, Pittsburgh, PA 15260 USA
关键词
Protein-protein interactions; small molecules; high-throughput screening; fragment-based drug discovery; peptide-based drug discovery; protein secondary structure mimetics; computer-aided drug discovery; VITRO DISPLAY TECHNOLOGIES; SMALL-MOLECULE INHIBITORS; EPO RECEPTOR COMPLEX; HIGH-THROUGHPUT; LEAD DISCOVERY; IN-VITRO; THERAPEUTIC PEPTIDES; LIGAND EFFICIENCY; STRUCTURAL BASIS; FAMILY PROTEINS;
D O I
暂无
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Protein-protein interactions are involved in most of the essential processes that occur in living organisms from cell motility to DNA replication, which makes them interesting targets for drug discovery. However, due to the lack of deep pockets, and the large contact surfaces involved in these interactions, they are considered challenging targets and have been often times dismissed as "undruggable". Nonetheless, significant efforts in pharmaceutical and academic laboratories have been devoted to finding ways to exploit protein-protein interactions as drug targets. This article provides an overview of the principles underlying the main general strategies for discovering small-molecule modulators of protein-protein interactions, namely: high-throughput screening, fragment-based drug discovery, peptide-based drug discovery, protein secondary structure mimetics, and computer-aided drug discovery. In addition, examples of successful discovery of modulators of protein-protein interactions are discussed for each of those strategies.
引用
收藏
页码:248 / 257
页数:10
相关论文
共 122 条
[1]   The Bcl-2 protein family: Arbiters of cell survival [J].
Adams, JM ;
Cory, S .
SCIENCE, 1998, 281 (5381) :1322-1326
[2]   Converting a peptide into a drug: Strategies to improve stability and bioavailability [J].
Adessi, C ;
Soto, C .
CURRENT MEDICINAL CHEMISTRY, 2002, 9 (09) :963-978
[3]   Peptidomimetics and Peptide Backbone Modifications [J].
Ahn, Jung-Mo ;
Boyle, Nicholas A. ;
MacDonald, Mary T. ;
Janda, Kim D. .
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2002, 2 (05) :463-473
[4]   An improved relaxed complex scheme for receptor flexibility in computer-aided drug design [J].
Amaro, Rommie E. ;
Baron, Riccardo ;
McCammon, J. Andrew .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2008, 22 (09) :693-705
[5]   In vitro display technologies:: novel developments and applications [J].
Amstutz, P ;
Forrer, P ;
Zahnd, C ;
Plückthun, A .
CURRENT OPINION IN BIOTECHNOLOGY, 2001, 12 (04) :400-405
[6]   The process of structure-based drug design [J].
Anderson, AC .
CHEMISTRY & BIOLOGY, 2003, 10 (09) :787-797
[7]  
[Anonymous], 1990, M 196 1988 LOS ANG C
[8]   Design and modular parallel synthesis of a MCR derived α-helix mimetic protein-protein interaction inhibitor scaffold [J].
Antuch, W ;
Menon, S ;
Chen, QZ ;
Lu, YC ;
Sakamuri, S ;
Beck, B ;
Schauer-Vukasinovic, V ;
Agarwal, S ;
Hess, S ;
Dömling, A .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (06) :1740-1743
[9]   Protein-protein interactions and cancer: small molecules going in for the kill [J].
Arkin, M .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2005, 9 (03) :317-324
[10]   Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream [J].
Arkin, MR ;
Wells, JA .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (04) :301-317